Cargando…

Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies

Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome. Often, HE causes cognitive and motor dysfunctions due to an acute or chronic insufficiency of the liver or a shunting between the hepatic portal vein and systemic vasculature. Liver damage induces peripheral changes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Santos, Rafaela Pinto Coelho, Toscano, Eliana Cristina de Brito, Rachid, Milene Alvarenga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371400/
https://www.ncbi.nlm.nih.gov/pubmed/37487550
http://dx.doi.org/10.1055/s-0043-1767819
_version_ 1785078139162984448
author Santos, Rafaela Pinto Coelho
Toscano, Eliana Cristina de Brito
Rachid, Milene Alvarenga
author_facet Santos, Rafaela Pinto Coelho
Toscano, Eliana Cristina de Brito
Rachid, Milene Alvarenga
author_sort Santos, Rafaela Pinto Coelho
collection PubMed
description Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome. Often, HE causes cognitive and motor dysfunctions due to an acute or chronic insufficiency of the liver or a shunting between the hepatic portal vein and systemic vasculature. Liver damage induces peripheral changes, such as in the metabolism and peripheral inflammatory responses that trigger exacerbated neuroinflammation. In experimental models, anti-inflammatory strategies have demonstrated neuroprotective effects, leading to a reduction in HE-related cognitive and motor impairments. In this scenario, a growing body of evidence has shown that peripheral and central nervous system inflammation are promising preclinical targets. In this review, we performed an overview of FDA-approved drugs and natural compounds which are used in the treatment of other neurological and nonneurological diseases that have played a neuroprotective role in experimental HE, at least in part, through anti-inflammatory mechanisms. Despite the exciting results from animal models, the available data should be critically interpreted, highlighting the importance of translating the findings for clinical essays.
format Online
Article
Text
id pubmed-10371400
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Thieme Revinter Publicações Ltda.
record_format MEDLINE/PubMed
spelling pubmed-103714002023-07-27 Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies Santos, Rafaela Pinto Coelho Toscano, Eliana Cristina de Brito Rachid, Milene Alvarenga Arq Neuropsiquiatr Hepatic encephalopathy (HE) is a potentially reversible neuropsychiatric syndrome. Often, HE causes cognitive and motor dysfunctions due to an acute or chronic insufficiency of the liver or a shunting between the hepatic portal vein and systemic vasculature. Liver damage induces peripheral changes, such as in the metabolism and peripheral inflammatory responses that trigger exacerbated neuroinflammation. In experimental models, anti-inflammatory strategies have demonstrated neuroprotective effects, leading to a reduction in HE-related cognitive and motor impairments. In this scenario, a growing body of evidence has shown that peripheral and central nervous system inflammation are promising preclinical targets. In this review, we performed an overview of FDA-approved drugs and natural compounds which are used in the treatment of other neurological and nonneurological diseases that have played a neuroprotective role in experimental HE, at least in part, through anti-inflammatory mechanisms. Despite the exciting results from animal models, the available data should be critically interpreted, highlighting the importance of translating the findings for clinical essays. Thieme Revinter Publicações Ltda. 2023-07-24 /pmc/articles/PMC10371400/ /pubmed/37487550 http://dx.doi.org/10.1055/s-0043-1767819 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Santos, Rafaela Pinto Coelho
Toscano, Eliana Cristina de Brito
Rachid, Milene Alvarenga
Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
title Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
title_full Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
title_fullStr Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
title_full_unstemmed Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
title_short Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
title_sort anti-inflammatory strategies for hepatic encephalopathy: preclinical studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10371400/
https://www.ncbi.nlm.nih.gov/pubmed/37487550
http://dx.doi.org/10.1055/s-0043-1767819
work_keys_str_mv AT santosrafaelapintocoelho antiinflammatorystrategiesforhepaticencephalopathypreclinicalstudies
AT toscanoelianacristinadebrito antiinflammatorystrategiesforhepaticencephalopathypreclinicalstudies
AT rachidmilenealvarenga antiinflammatorystrategiesforhepaticencephalopathypreclinicalstudies